Literature DB >> 20855724

Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production.

Jennifer H Moffatt1, Marina Harper, Paul Harrison, John D F Hale, Evgeny Vinogradov, Torsten Seemann, Rebekah Henry, Bethany Crane, Frank St Michael, Andrew D Cox, Ben Adler, Roger L Nation, Jian Li, John D Boyce.   

Abstract

Infections caused by multidrug-resistant (MDR) Gram-negative bacteria represent a major global health problem. Polymyxin antibiotics such as colistin have resurfaced as effective last-resort antimicrobials for use against MDR Gram-negative pathogens, including Acinetobacter baumannii. Here we show that A. baumannii can rapidly develop resistance to polymyxin antibiotics by complete loss of the initial binding target, the lipid A component of lipopolysaccharide (LPS), which has long been considered to be essential for the viability of Gram-negative bacteria. We characterized 13 independent colistin-resistant derivatives of A. baumannii type strain ATCC 19606 and showed that all contained mutations within one of the first three genes of the lipid A biosynthesis pathway: lpxA, lpxC, and lpxD. All of these mutations resulted in the complete loss of LPS production. Furthermore, we showed that loss of LPS occurs in a colistin-resistant clinical isolate of A. baumannii. This is the first report of a spontaneously occurring, lipopolysaccharide-deficient, Gram-negative bacterium.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20855724      PMCID: PMC2981238          DOI: 10.1128/AAC.00834-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  36 in total

1.  Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii.

Authors:  Jian Li; Craig R Rayner; Roger L Nation; Roxanne J Owen; Denis Spelman; Kar Eng Tan; Lisa Liolios
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

Review 2.  Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections.

Authors:  Jian Li; Roger L Nation; John D Turnidge; Robert W Milne; Kingsley Coulthard; Craig R Rayner; David L Paterson
Journal:  Lancet Infect Dis       Date:  2006-09       Impact factor: 25.071

3.  Gram-negative outer and inner membrane models: insertion of cyclic cationic lipopeptides.

Authors:  Adrià Clausell; Maria Garcia-Subirats; Montserrat Pujol; M Antonia Busquets; Francesc Rabanal; Yolanda Cajal
Journal:  J Phys Chem B       Date:  2007-01-25       Impact factor: 2.991

4.  Moraxella catarrhalis bacterium without endotoxin, a potential vaccine candidate.

Authors:  Daxin Peng; Wenzhou Hong; Biswa P Choudhury; Russell W Carlson; Xin-Xing Gu
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

5.  Structural analysis of the lipopolysaccharide of Pasteurella multocida strain VP161: identification of both Kdo-P and Kdo-Kdo species in the lipopolysaccharide.

Authors:  Frank St Michael; Jianjun Li; Evgeny Vinogradov; Suzon Larocque; Marina Harper; Andrew D Cox
Journal:  Carbohydr Res       Date:  2005-01-17       Impact factor: 2.104

6.  Fis is essential for capsule production in Pasteurella multocida and regulates expression of other important virulence factors.

Authors:  Jason A Steen; Jennifer A Steen; Paul Harrison; Torsten Seemann; Ian Wilkie; Marina Harper; Ben Adler; John D Boyce
Journal:  PLoS Pathog       Date:  2010-02-05       Impact factor: 6.823

7.  Two distinct clones of carbapenem-resistant Acinetobacter baumannii isolates from Korean hospitals.

Authors:  Young Kyoung Park; Ji Young Choi; Sook-In Jung; Kyong-Hwa Park; Hyuck Lee; Dong Sik Jung; Sang Taek Heo; Shin-Woo Kim; Hyun-Ha Chang; Hae Suk Cheong; Doo Ryeon Chung; Kyong Ran Peck; Jae-Hoon Song; Kwan Soo Ko
Journal:  Diagn Microbiol Infect Dis       Date:  2009-08       Impact factor: 2.803

8.  Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004).

Authors:  A C Gales; R N Jones; H S Sader
Journal:  Clin Microbiol Infect       Date:  2006-04       Impact factor: 8.067

9.  Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.

Authors:  Mark D Adams; Gabrielle C Nickel; Saralee Bajaksouzian; Heather Lavender; A Rekha Murthy; Michael R Jacobs; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2009-06-15       Impact factor: 5.191

10.  New insights into Acinetobacter baumannii pathogenesis revealed by high-density pyrosequencing and transposon mutagenesis.

Authors:  Michael G Smith; Tara A Gianoulis; Stefan Pukatzki; John J Mekalanos; L Nicholas Ornston; Mark Gerstein; Michael Snyder
Journal:  Genes Dev       Date:  2007-03-01       Impact factor: 11.361

View more
  272 in total

Review 1.  Bugs, drugs and chemical genomics.

Authors:  Terry Roemer; Julian Davies; Guri Giaever; Corey Nislow
Journal:  Nat Chem Biol       Date:  2011-12-15       Impact factor: 15.040

2.  Host-microbe interactions that shape the pathogenesis of Acinetobacter baumannii infection.

Authors:  Brittany L Mortensen; Eric P Skaar
Journal:  Cell Microbiol       Date:  2012-06-14       Impact factor: 3.715

3.  Rapid and Consistent Evolution of Colistin Resistance in Extensively Drug-Resistant Pseudomonas aeruginosa during Morbidostat Culture.

Authors:  Bianca Dößelmann; Matthias Willmann; Matthias Steglich; Boyke Bunk; Ulrich Nübel; Silke Peter; Richard A Neher
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

Review 4.  Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections.

Authors:  J Alexander Viehman; M Hong Nguyen; Yohei Doi
Journal:  Drugs       Date:  2014-08       Impact factor: 9.546

5.  Rapid killing of Acinetobacter baumannii by polymyxins is mediated by a hydroxyl radical death pathway.

Authors:  Timothy R Sampson; Xiang Liu; Max R Schroeder; Colleen S Kraft; Eileen M Burd; David S Weiss
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

Review 6.  Rescuing the Last-Line Polymyxins: Achievements and Challenges.

Authors:  Sue C Nang; Mohammad A K Azad; Tony Velkov; Qi Tony Zhou; Jian Li
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

7.  Lipopolysaccharide-deficient Acinetobacter baumannii shows altered signaling through host Toll-like receptors and increased susceptibility to the host antimicrobial peptide LL-37.

Authors:  Jennifer H Moffatt; Marina Harper; Ashley Mansell; Bethany Crane; Timothy C Fitzsimons; Roger L Nation; Jian Li; Ben Adler; John D Boyce
Journal:  Infect Immun       Date:  2012-12-17       Impact factor: 3.441

8.  R93P Substitution in the PmrB HAMP Domain Contributes to Colistin Heteroresistance in Escherichia coli Isolates from Swine.

Authors:  Qihong Kuang; Dandan He; Huarun Sun; Huihui Hu; Fulin Li; Wenya Li; Gongzheng Hu; Hua Wu; Li Yuan
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

9.  Pan-transcriptomic analysis identified common differentially expressed genes of Acinetobacter baumannii in response to polymyxin treatments.

Authors:  Mengyao Li; Su Mon Aye; Maizbha Uddin Ahmed; Mei-Ling Han; Chen Li; Jiangning Song; John D Boyce; David R Powell; Mohammad A K Azad; Tony Velkov; Yan Zhu; Jian Li
Journal:  Mol Omics       Date:  2020-05-29

10.  Activities of vancomycin-containing regimens against colistin-resistant Acinetobacter baumannii clinical strains.

Authors:  Jessica A O'Hara; Lauretta A Ambe; Leila G Casella; Bethany M Townsend; Mark R Pelletier; Robert K Ernst; Robert M Q Shanks; Yohei Doi
Journal:  Antimicrob Agents Chemother       Date:  2013-02-19       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.